Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in ADIL held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 24K | $43K | -84.4% | 2.527% | 0.00% |
| 2 | VANGUARD FIDUCIARY TRUST CO | 6K | $11K | — | 0.613% | 0.00% |
| 3 | Manchester Capital Management LLC | 2K | $3K | -96.0% | 0.200% | 0.00% |
| 4 | Tower Research Capital LLC (TRC) | 1K | $2K | +1.1% | 0.141% | 0.00% |
| 5 | BlackRock, Inc. | 1K | $2K | -96.0% | 0.116% | 0.00% |
| 6 | UBS Group AG | 542 | $970 | -94.1% | 0.056% | 0.00% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 361 | $646 | — | 0.038% | 0.00% |
| 8 | MORGAN STANLEY | 50 | $90 | +455.6% | 0.005% | 0.00% |
| 9 | SBI Securities Co., Ltd. | 47 | $84 | -95.9% | 0.005% | 0.00% |
| 10 | Caitong International Asset Management Co., Ltd | 15 | $27 | — | 0.002% | 0.00% |
| 11 | WELLS FARGO & COMPANY/MN | 6 | $11 | -96.3% | 0.001% | 0.00% |
| 12 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 4 | $7 | — | 0.000% | 0.00% |
| 13 | HARBOUR INVESTMENTS, INC. | 3 | $5 | -97.0% | 0.000% | 0.00% |
| 14 | Abound Wealth Management | 1 | $2 | -96.3% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ADIL — a direct measure of their conviction.
Filings activity in ADIL during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new ADIL position in Q1 2026
Institutions that fully closed their ADIL position in Q1 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 14 | 39% | 2.22% | 24.49 pp | $0M | 92% |
| Q4 2025 | 23 | +44% | 26.71% | +19.33 pp | $1M | +262% |
| Q3 2025 | 16 | 5.9% | 7.38% | +5.10 pp | $0M | +224% |
| Q2 2025 | 17 | +21% | 2.28% | 2.42 pp | $0M | 51% |
| Q1 2025 | 14 | 6.7% | 4.70% | 4.71 pp | $0M | 50% |
| Q4 2024 | 15 | +36% | 9.41% | +2.76 pp | $0M | +41% |
| Q3 2024 | 11 | 27% | 6.65% | 3.44 pp | $0M | 34% |
| Q2 2024 | 15 | — | 10.09% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as the highest-conviction signal because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 2026 | Young Wendy B. | Buy | 36K | $2.75 | $100K |
Quick answers to the most common questions about buying ADIL stock.
Based on Q1 2026 13F filings, institutional ownership of Adial Pharmaceuticals, Inc. stands at 2.2%, held across 14 reporting institutions.
GEODE CAPITAL MANAGEMENT, LLC is the largest reported institutional holder of ADIL, with approximately 24,249 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of ADIL.
Our composite Smart Money Score for ADIL is 15 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
4 institutions opened new positions in ADIL during Q1 2026, while 13 fully exited. 3 added to existing positions and 7 trimmed.
ADIL institutional ownership fell by 24.49 percentage points quarter-over-quarter, with a net change of -9 holders.
The top 10 institutions account for 100.0% of all reported 13F value in ADIL, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Adial Pharmaceuticals, Inc. (ADIL) Institutional Ownership